Abstract
T lymphocytes are critical mediators of the adaptive immune system and have the capacity to serve as therapeutic agents in the areas of transplant and cancer immunotherapy. While T cells can be isolated and expanded from patients, T cells derived in vitro from both hematopoietic stem/progenitor cells (HSPCs) and human pluripotent stem cells (hPSCs) offer great potential advantages in generating a self-renewing source of T cells that can be readily genetically modified. T-cell differentiation in vivo is a complex process requiring tightly regulated signals; providing the correct signals in vitro to induce T-cell lineage commitment followed by their development into mature, functional, single positive T cells, is similarly complex. In this review, we discuss current methods for the in vitro derivation of T cells from murine and human HSPCs and hPSCs that use feeder-cell and feeder-cell-free systems. Furthermore, we explore their potential for adoption for use in T-cell-based therapies.
Original language | English (US) |
---|---|
Pages (from-to) | 3174-3180 |
Number of pages | 7 |
Journal | Stem Cells |
Volume | 33 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2015 |
Bibliographical note
Publisher Copyright:© 2015 AlphaMed Press.
Keywords
- CD34-+-
- Cell culture
- Cord blood
- Differentiation
- Embryonic stem cells
- Hematopoietic stem cells
- Induced pluripotent stem cells
- T cells
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural
- Review